FLORIDA Trial
|
High Density Lipoprotein Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Clinical Trials |
|
Case Studies |
|
FLORIDA Trial On the Web |
|
American Roentgen Ray Society Images of FLORIDA Trial |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Objective
To assess the effect of fluvastatin on residual ischemia after acute myocardial infarction.
Methods
FLuvastatin On Risk Diminishment after Acute myocardial infarction (FLORIDA) trial was a randomized, placebo-controlled, double-blinded, parallel study that enrolled 540 patients with an acute myocardial infarction and serum cholesterol <251 mg/dL. The trial used ambulatory electrocardiographic (AECG) monitoring to measure ischemia over 48-h at baseline, after 6 weeks and at 12 months. All the patients were randomized to treatment with either fluvastatin or placebo.
Results
The following were the results of the trial:
- At 12 months, the serum total cholesterol (TC) level was reduced by 13% and LDL-C by 21% in the fluvastatin treatment group compared to a 9% rise in the placebo group.
- AECG monitoring at baseline showed ischemia in 11% of the patients. After 6 weeks, 32/48 (67%), and 12 months 35/46 (76%) of the patients with ischemia on the baseline AECG, no longer showed signs of ischemia.
Conclusion
As compared to placebo, fluvastatin treatment did not affect ischemia on AECG, nor the occurrence of any major clinical events.[1]
References
- ↑ Liem AH, van Boven AJ, Veeger NJ; et al. (2002). "Effect of fluvastatin on ischaemia following acute myocardial infarction: a randomized trial". European Heart Journal. 23 (24): 1931–7. PMID 12473255. Unknown parameter
|month=ignored (help)